



## THE INTERNATIONAL MAOI EXPERT GROUP,

- Having formulated the first [international expert consensus guideline](#) on the use of the classic monoamine oxidase inhibitors (MAOIs) phenelzine, tranylcypromine, and isocarboxazid in treatment-resistant depression,
  - Having formulated the accompanying [low-tyramine dietary guideline](#) as an up-to-date reference tool for physicians and patients,
  - Having recognised the discrepancies between the unique evidence-based merits of the MAOI antidepressants on the one hand, and the low and ever-dwindling prescription rates on the other,
  - Having recognised the limitations in patient access to the MAOI antidepressants due to insufficiencies in their availability and affordability in many national drug markets,
- 1 Recommends, in line with the previously published [position statement](#), that:
    - (a) National regulatory bodies and governmental agencies, professional stakeholder-groups, and pharmaceutical industry representatives come to a collaborative understanding of the above-mentioned limitations and seek to remedy them,
    - (b) Issuers of guidelines and advice on MAOI use undertake the necessary steps to update their content to align it with the state-of-the-art developments in MAOI research as expressed in the international expert consensus guideline,
    - (c) Medical educators take steps to update the contents of their curricula to align the contents more closely with the treatment recommendations outlined in the international expert consensus guideline.
  - 2 Recommends that the above-mentioned parties contact the International MAOI Expert Group secretariat for guidance on these matters ([secretariat@maoiexperts.org](mailto:secretariat@maoiexperts.org)).

As submitted by the Advisory Panel

As ratified by the Presiding Council

*This statement expresses the position of the International MAOI Expert Group in joint assembly.*